Single-molecule real-time sequencing

Global Long Read Sequencing Market Research Report 2023-2030: Transformative Advantages, Clinical Applications, and Data Analysis Innovations - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Biotechnology, Technology, Manufacturing, Health, Pharmaceutical, Other Science, Research, Other Manufacturing, Nanotechnology, Genetics, Science, Molecule, DNA, Workflow, Prevalence, Single-molecule real-time sequencing, SARS-CoV-2, Coronavirus, COVID-19, DSM-IV codes, Genomics, USD, Proteomics, LRS, SMRT, Traction, Investment, Application, Nanopore sequencing, Map, WGS, Nanopore, Knowledge, Oxford Nanopore Technologies, D, Speciality chemicals, Pharmaceutical industry, Vaccine, Medical imaging, Antibiotics, Fine chemical

The "Long Read Sequencing Market Size, Share & Trends Analysis Report By Product, By Technology (Nanopore Sequencing), By Workflow, By Application, By End-Use, By Region And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Long Read Sequencing Market Size, Share & Trends Analysis Report By Product, By Technology (Nanopore Sequencing), By Workflow, By Application, By End-Use, By Region And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global long read sequencing market size is expected to reach USD 3.78 billion by 2030, registering a CAGR of 30.92%
    In the realm of pharmaceutical modification, the significance of sequencing methods has never been more pronounced, underscored by the growing market value attributed to the expanding knowledge of long read sequencing.
  • Against this backdrop, ongoing research activities not only offer manufacturers a competitive edge in crafting advanced elongated read sequencing but also pave the way for an array of unexplored opportunities within the long read sequencing market.
  • In addition, the limitations of clinical disease research based on next-generation sequencing could be partially overcome by these technologies.

PacBio transforms access to the epigenome and streamlines workflows

Retrieved on: 
Thursday, April 21, 2022
Molecule, Genetic variation, Biology, DNA, Workflow, U.S. Securities and Exchange Commission, Microbiology, Pediatrics, Security (finance), NASDAQ, SMRT, Bloomberg Distinguished Professorships, Research, Human, Private Securities Litigation Reform Act, University of Missouri–Kansas City School of Medicine, Associate, Automation, GLOBE, Sequel, Doctor of Philosophy, Apple IIe, Abraxis BioScience, CpG, High fidelity, Biomedical Research, Securities Exchange Act of 1934, Genome, Technology, Pacific Biosciences, Gene, Kaay Raav Tumhi, Methylation, Single-molecule real-time sequencing, Computer science, Epigenome, Disease, University, Health, CGC, University of Missouri, Johns Hopkins University, DNA methylation, Fine chemical, Video game, Medical imaging, Antibiotics

As a result, scientists gain access to the epigenome with zero additional cost, effort, or complexity.

Key Points: 
  • As a result, scientists gain access to the epigenome with zero additional cost, effort, or complexity.
  • This advance will unlock important new opportunities across a broad range of applications in fundamental and applied biological science.
  • Historically, access to the epigenome has been difficult and required sacrifices in read lengths, accuracy, and completeness while adding workflow complexity.
  • Streamlining workflows is a key focus for PacBio, and this latest update makes it easier to perform HiFi sequencing.

PacBio and Children’s Mercy Kansas City Expand Collaboration Taking a Multi-Omics Approach to Characterize Rare Disease

Retrieved on: 
Thursday, April 21, 2022
Molecule, Magnet, Genetic variation, News, Lists of diseases, DNA, Faculty, U.S. Securities and Exchange Commission, Degenerative disease, Twitter, Genetics in Medicine, NASDAQ, Microbiology, Research, Security (finance), MD, Caregiver, Private Securities Litigation Reform Act, RNA, Hospital, YouTube, GLOBE, Doctor of Philosophy, Education, Apple IIe, Abraxis BioScience, Patient, Sequel, High fidelity, U.S. News & World Report, LinkedIn, Biomedical Research, Securities Exchange Act of 1934, Genome, Technology, Method, Pacific Biosciences, WGS, Gene, Single-molecule real-time sequencing, Instagram, Disease, Child, Methylation, Time, Pharmaceutical industry, Antibiotics, Medical imaging, Medicine, Genetics, Facebook

Our continued collaboration with Childrens Mercy is a great example of PacBios technology being used at breadth, depth, and scale, said Christian Henry, President and Chief Executive Officer of PacBio.

Key Points: 
  • Our continued collaboration with Childrens Mercy is a great example of PacBios technology being used at breadth, depth, and scale, said Christian Henry, President and Chief Executive Officer of PacBio.
  • This new collaboration looks to build on that success by studying new methods for the potential detection of rare diseases.
  • Childrens Mercy will employ the Iso-Seq method to characterize isoforms that may be associated with disease.
  • With this new collaboration, Childrens Mercy will deploy those instruments to look further with multi-omics approaches for methylation and RNA sequencing.

PacBio to Report First Quarter 2022 Financial Results on May 4, 2022

Retrieved on: 
Wednesday, April 20, 2022
Molecule, NASDAQ, Genetic variation, Biomedical Research, Single-molecule real-time sequencing, Pacific Biosciences, Microbiology, Internet service provider, Antibiotics

If using the dial-in option, please dial into the call five to ten minutes prior to start time using the appropriate number above and ask to join the PacBio Q1 Earnings Call.

Key Points: 
  • If using the dial-in option, please dial into the call five to ten minutes prior to start time using the appropriate number above and ask to join the PacBio Q1 Earnings Call.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate long-read sequencing.
  • Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
  • For more information, please visit www.pacb.com and follow @PacBio .

HiFi Reads Enable Telomere-to-Telomere Consortium to Fill the Final Gaps in the Human Genome, Heralding a New Era of Research into Genetic Diseases and Human Biology

Retrieved on: 
Thursday, March 31, 2022
Molecule, Company, Work, Human, NASDAQ, DNA, Facioscapulohumeral muscular dystrophy, National Human Genome Research Institute, Research, Abraxis BioScience, Lists of diseases, Genomics, Reading, Basic Law: Israel as the Nation-State of the Jewish People, Health, Consortium, U.S. Securities and Exchange Commission, Preprint, Private Securities Litigation Reform Act, Pacific Biosciences, Genome, Security (finance), Biomedical Research, Technology, Biology, FRG1, Securities Exchange Act of 1934, High fidelity, Genetic variation, GLOBE, Gene, Microbiology, State, FSHD, Disease, Human Genome Project, Single-molecule real-time sequencing, Antibiotics, Agriculture, Science

The newly assembled regions cover a full eight percent of the human genome previously inaccessible with earlier technologies.

Key Points: 
  • The newly assembled regions cover a full eight percent of the human genome previously inaccessible with earlier technologies.
  • The T2T Consortiums work could help scientists better understand human biology and evolution.
  • The complete, T2T assembly of a human genome marks a new era of genomics where no region of the genome is beyond reach.
  • In addition, a more complete reference genome may translate to more discovery, setting a new standard in genomics built on PacBio HiFi sequencing.

PacBio Supports SickKids to Investigate Use of HiFi Sequencing in Undiagnosed Genetic Conditions

Retrieved on: 
Monday, February 28, 2022
Molecule, GLOBE, Securities Exchange Act of 1934, TCAG, Autism, Single-molecule real-time sequencing, Security (finance), Abraxis BioScience, NASDAQ, Centre for Applied Genomics, Diagnosis, Hospital, Whole genome sequencing, Genomics, Research, Genome, Company, Pacific Biosciences, Associate, Genetic testing, Birth, U.S. Securities and Exchange Commission, Hospital for Sick Children, Lists of diseases, Biomedical Research, Intellectual disability, Structural variation in the human genome, High fidelity, Hospital for Sick Children (Toronto), Clinical Laboratory, Technology, Genetic variation, Microbiology, Private Securities Litigation Reform Act, The Centre, Vaccine, Antibiotics

Samples that will be examined using HiFi WGS were previously sequenced using short-read DNA sequencing technology, but still lack the identification of a disease-causing variant.

Key Points: 
  • Samples that will be examined using HiFi WGS were previously sequenced using short-read DNA sequencing technology, but still lack the identification of a disease-causing variant.
  • SickKids will use HiFi WGS to analyze samples from research participants who are highly suspected to have a genetic condition but have not yet received a diagnosis despite previous genetic testing, including srWGS.
  • The team will explore whether HiFi WGS can detect potential genetic causes for a range of conditions, such as autism spectrum disorder and congenital diseases.
  • PacBios technology has been used to help genetic disease researchers explain mysteries where other technologies could not, said Edd Lee, Director of Human Genomics at PacBio.

PacBio Grants Equity Incentive Award to New Employee

Retrieved on: 
Friday, February 25, 2022
Molecule, GLOBE, Effective date, Single-molecule real-time sequencing, Abraxis BioScience, NASDAQ, Research, Pacific Biosciences, Financial compensation, Pacific Ocean, RSU, Biomedical Research, Genetic variation, Microbiology, Option

The options have an exercise price of $10.32 per share, which is equal to the closing price of PacBio common stock on February 22, 2022 (the Effective Date).

Key Points: 
  • The options have an exercise price of $10.32 per share, which is equal to the closing price of PacBio common stock on February 22, 2022 (the Effective Date).
  • The option grant and the award of RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the award agreements entered into with the employee.
  • Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
  • For more information, please visit www.pacb.com and follow @PacBio .

PacBio Welcomes Dr. Michael Eberle as Vice President of Computational Biology

Retrieved on: 
Wednesday, February 23, 2022
Molecule, GLOBE, Securities Exchange Act of 1934, Single-molecule real-time sequencing, Security (finance), NASDAQ, University, Research, Data science, Genome, Pacific Biosciences, U.S. Securities and Exchange Commission, Genomics, Biomedical Research, Computational biology, Forward-looking statement, Genetic variation, University of Washington Information School, History, Microbiology, Private Securities Litigation Reform Act, Management, Antibiotics, Illumina, Abraxis BioScience, Physics, Science

MENLO PARK, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, welcomes Michael Eberle, Ph.D., as Vice President of Computational Biology.

Key Points: 
  • MENLO PARK, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, welcomes Michael Eberle, Ph.D., as Vice President of Computational Biology.
  • Michael will be responsible for leading the companys bioinformatics and data sciences program to enhance PacBios genomic analysis offerings.
  • For the last 15 years, Michael has been a leader in the research and development organization at Illumina, most recently as a Vice President and Distinguished Scientist.
  • There has never been a more exciting time to work in genomics than today, the pace of discovery and its potential impact improving the human condition is unparalleled in our history, said Michael Eberle, Ph.D., Vice President of Computational Biology at PacBio.

PacBio to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 9, 2022
Molecule, Single-molecule real-time sequencing, NASDAQ, Genetic variation, Biomedical Research, GLOBE, Pacific Biosciences, Abraxis BioScience, Microbiology, Conference, Video game

A replay of the webcasts will be available for at least 30 days following the presentation.

Key Points: 
  • A replay of the webcasts will be available for at least 30 days following the presentation.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate sequencing platforms.
  • Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
  • For more information please visit www.pacb.com and follow @PacBio .

PacBio to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022

Retrieved on: 
Tuesday, February 1, 2022
Molecule, Biomedical Research, Microbiology, Genetic variation, Single-molecule real-time sequencing, NASDAQ, Pacific Biosciences, List of life sciences, Antibiotics

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate sequencing platforms.

Key Points: 
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate sequencing platforms.
  • The companys innovative instruments are based on Single Molecule, Real-Time (SMRT) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism.
  • Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
  • For more information please visit www.pacb.com and follow @PacBio .